Aspira Women`s Health Inc Stock

$0.39

0.97%

Nasdaq, Thu, Aug 21 2025

ISIN

US04537Y1091

Symbol

AWH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

Aspira Women`s Health Inc Stock price

$0.39

-41.01 99.06% 5Y

Nasdaq, Closing price Thu, Aug 21 2025

-0.00 0.97%

ISIN

US04537Y1091

Symbol

AWH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

Enterprise Value

Net debt

$350.0k

Cash

$1.8m

Shares outstanding

17.4m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

P/B

Financial Health

Equity Ratio

-46.7%

Return on Equity

510.9%

ROCE

-81,390.0%

ROIC

Debt/Equity

-0.8

Financials (TTM | estimate)

Revenue

$9.2m | $18.3m

EBITDA

$-16.2m | -

EBIT

$-16.3m | $-14.0m

Net Income

$-13.1m | $-10.0m

Free Cash Flow

$-12.2m

Growth (TTM | estimate)

Revenue

0.2% | 99.8%

EBITDA

13.2% | -

EBIT

13.7% | 13.8%

Net Income

21.6% | 23.5%

Free Cash Flow

23.7%

EPS

$-0.8

FCF per Share

$-0.7

Short interest

1.8%

Employees

Rev per Employee

$140.0k

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

Get Started for Free Today

Aspira Women`s Health Inc Stock Analysis

Unlock Scores for Free

??

5 Analysts have issued a Aspira Women`s Health Inc forecast:

4x Buy

80%

1x Hold

20%

More details on Analyst Estimates Including Price Targets

5 Analysts have issued a Aspira Women`s Health Inc forecast:

Buy

80%

Hold

20%

Analyst Estimates with Stock Price Targets

Financial data from Aspira Women`s Health Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	9.18 9.18	0% 0% 100%
- Direct Costs	3.70 3.70	5% 5% 40%
Gross Profit	5.48 5.48	4% 4% 60%
- Selling and Administrative Expenses	18 18	8% 8% 201%
- Research and Development Expense	3.27 3.27	19% 19% 36%
EBITDA	-16 -16	13% 13% -176%
- Depreciation and Amortization	0.09 0.09	55% 55% 1%
EBIT (Operating Income) EBIT	-16 -16	14% 14% -177%
Net Profit	-13 -13	22% 22% -143%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Aspira Women`s Health Inc Stock News

Neutral

Accesswire

●

9 days ago

Aspira Announces Second Quarter 2025 Financial Results and Provides Business Update

AUSTIN, TX / ACCESS Newswire / August 13, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three and six months ended June 30, 2025. The Company also reported early progress un...

Neutral

Accesswire

●

about one month ago

Aspira Women's Health Announces Appointment of Jane Pine Wood to the Board of Directors

AUSTIN, TX / ACCESS Newswire / July 15, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (QTCQB:AWHL), an AI enhanced bio-analytical based women's health company focused on delivering the leading tools critical to gynecologic disease diagnostics and disease management, today announced the appointment of Jane Pine Wood to the Board of Directors, effective July 11, 2025. "We are plea...

Neutral

Accesswire

●

2 months ago

Aspira Women's Health Partners with Dorsata to Offer Access to 300+ Women's Health Practices, 1.5 Million + New Patients

Aspira and Dorsata Launch Clinical Workflow Tool for Adnexal Masses, Now Live for All Dorsata Clients, Adnexal Mass Evidence-Based Decision Support AUSTIN, TX AND WASHINGTON, DC / ACCESS Newswire / June 17, 2025 / Aspira Women's Health Inc. a bio-analytical-based women's health company focused on gynecologic disease diagnostics, and Dorsata, a leading clinical decision-support and provider work...

More Aspira Women`s Health Inc News

Company Profile

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company provides sells OVA1, Overa, and Ova1PLUS risk of malignancy tests for ovarian cancer. It also offers ASPiRA GenetiX, a genetic test for specific women's health diseases. In addition, the company owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, it is developing diagnostic algorithms, as well as a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. The company serves physicians, physician office laboratories, and hospital laboratories. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was founded in 1993 and is headquartered in Austin, Texas.

Head office	United States
CEO	Michael Buhle
Employees	66
Founded	1993
Website	aspirawh.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now